AXT, Inc. sees its shares climb following the appointment of Leonard J. LeBlanc as independent Chair of its Audit Committee, a move analysts say bolsters corporate oversight and may appeal to institutional investors.
Wall Street is recalibrating its view on Intel, with a significant boost in the consensus price target reflecting renewed confidence in the chipmaker's strategic turnaround and long-term growth prospects.
Lemonade's stock soared in January, propelled by the launch of a novel, usage-based insurance plan for Tesla vehicles that slashes premiums when Full Self-Driving is engaged, signaling a strategic pivot towards data-driven, autonomous future.
After a stellar 2025, mobile advertising tech leader AppLovin faced a perfect storm of challenges last month, including renewed short-seller allegations, sector-wide valuation pressures, and market jitters over Google's new AI game-creation tool.
While voice-AI firms like SoundHound capture headlines, data analytics giant Palantir Technologies leverages deep government ties and enterprise contracts to build a potentially more resilient growth narrative in the volatile AI sector.
Amidst record market levels, analysts highlight a select group of companies—from AI leaders to emerging fintech—with strong fundamentals and room for significant expansion.
The cost to insure against swings in South Korean equities has surged to unprecedented levels relative to US markets, signaling deep investor anxiety after a historic rally fueled by AI optimism shows signs of fatigue.
Azenta, Inc. is set to report its quarterly earnings before the market opens Wednesday. Analysts project stagnant year-over-year revenue, placing the spotlight on the company's ability to navigate a challenging market for life sciences tools and services.
Blue Bird Corporation (BLBD) is poised to release its latest quarterly results after Wednesday's market close. Investors will be watching to see if the manufacturer can maintain its pattern of outperforming Wall Street's forecasts amidst a mixed landscape for heavy equipment peers.
As PTC prepares to release its Q4 financial results, investors are weighing its strong historical performance against a turbulent market for vertical software stocks. Here’s the breakdown.
CME Group is set to report fourth-quarter earnings Wednesday morning, with analysts forecasting a 7.8% revenue increase. The derivatives exchange operator's performance may signal broader capital markets health as peers post mixed results.
Tenable Holdings, a leader in exposure management, reports its fourth-quarter earnings after the bell Wednesday. All eyes will be on whether the company can maintain its track record of revenue beats against a backdrop of slowing growth forecasts and a battered cybersecurity sector.
Arcellx shares have delivered stellar multi-year gains, prompting investors to question if the rally still has room to run. A deep dive into valuation metrics reveals a complex picture, with discounted cash flow models pointing to significant upside while price-to-book ratios suggest a more cautious stance.
Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, handing full development rights back to the Japanese partner. The strategic shift comes as Amgen's stock trades above most fair value estimates, raising questions about its current valuation amid pipeline recalibration.
Shares of cybersecurity firm Gen Digital have tumbled over 7% in a week, pushing its valuation metrics below industry averages. A deep dive into its cash flows and earnings multiples suggests the market may be undervaluing the consumer digital safety provider.
Shares of Coastal Financial (CCB) have tumbled over 13% in the past month, sparking debate among investors. While a proprietary valuation model suggests the stock is deeply undervalued, its premium P/E ratio tells a conflicting story. We examine the numbers and the broader context for regional banks.
Energy Recovery (ERII) sees its price target raised to $23 by analysts, reflecting increased confidence in the adoption timeline for its CO2 refrigeration technology, despite stable core valuation metrics. The shift underscores a nuanced market narrative focused on execution rather than a fundamental change in long-term prospects.
Vera Therapeutics appoints industry veteran Matt Skelton as Chief Commercial Officer, signaling a strategic pivot toward commercialization as its lead drug candidate for IgA nephropathy, atacicept, undergoes FDA Priority Review.
As Kulicke & Soffa prepares to release its fourth-quarter results, investors are watching to see if the semiconductor equipment specialist can meet elevated expectations amid a sector-wide rebound.
Aerospace and defense component maker Woodward, Inc. (WWD) is commanding investor attention following a robust first-quarter earnings beat, a significant dividend hike, and an upgraded full-year outlook. The strong results have propelled the stock to new highs, reigniting the debate over its valuation in a rapidly evolving industry.
